Background-Studies of renal denervation report disparate results. Meta-analysis by trial design may allow quantitative estimation of sources and magnitude of biases in denervation studies. Methods and Results-One hundred forty nonrandomized, 6 randomized open-label, and 2 randomized blinded studies were analyzed for 2 outcomes: (1) blood pressure changes for nonrandomized, open-label randomized, and blinded studies; and (2) quantification of 3 biases potentially contributing to apparent antihypertensive effects: (a) regression to the mean, (b) asymmetrical data handling, and (c) true blood pressure drops caused by something other than the tested therapy (confounding).
H ypertension remains a dominant modifiable risk factor of cardiovascular morbidity and mortality worldwide. Before medications were widely available, early reports of surgical sympathectomy reported large blood pressure reductions albeit with side effects that prevented widespread uptake. 1 Twenty-first century catheter technology, however, has revived this concept by enabling minimally invasive ablation of a part of the sympathetic nervous system subtending the kidneys, which have a key role in blood pressure regulation.
Renal denervation by catheter initially showed highly promising results, with drops in blood pressure of 30 mm Hg, 2, 3 seeming so large that some have said a blinded randomized trial might seem unnecessary and triggering the development of >50 different devices to provide renal denervation. With thousands of patients having now undergone the procedure, the largest trial of renal denervation, Symplicity HTN-3, caused surprise when it did not show a significant effect. 4 We have previously reported that the blood pressure drop reported in clinical trials of renal denervation seemed to vary with the design of the trial. [5] [6] [7] Study design is known to matter, but it is often assumed not to matter much when reported effect sizes are large. This is based on the assumption that the biases that amplify an underlying effect are not large enough to produce an effect from nothing.
The numerous studies of renal denervation provide a unique opportunity to assay the magnitude of the biases affecting clinical studies of the efficacy of therapies in the 21st century. This would be useful in planning future studies of novel therapies for any medical condition. In a study of patients undergoing a new therapy for hypertension, there
Unrepresentatively High Estimate of Pretherapy Blood Pressure
Studies of novel therapies for blood pressure sometimes, understandably, select patients on the basis of their blood pressure being higher than a certain threshold. Because of natural variability in blood pressure over time, such a selection process tends to preferentially select patients at times when their blood pressures are above their individual long-term averages. Subsequent blood pressures, being unselected, return to reflecting the individuals' long-term averages, causing a fall in observed pressures that is denoted regression to the mean.
Unrepresentatively Low Estimate of Post-Therapy Blood Pressure
In clinical practice, doctors measuring blood pressure after an efficacious intervention, but seeing no fall, report 8 that they would remeasure rather than document a seemingly incorrect value. If this process occurs in a research study, when the novel therapy is thought to be highly efficacious, it will lead to an unconscious tendency to document an unrepresentatively low post-treatment value. We term this asymmetrical data handling. In research practice, hypertension trials can combat this tendency by using automated blood pressure monitors with internal memory cards, ensuring standardized data handling by physicians. Alternatively, they may lay out a rigorous protocol insisting that data are not discarded, even if they seem unrepresentative. Enforcing such a protocol is difficult for manually documented values because day-to-day clinical practice relies on physicians using judgment.
A True Change in Blood Pressure But Not Attributable to the New Therapy Under Study
Even if baseline and final pressures are documented representatively, a fall does not necessarily mean that the intervention was biologically efficacious. For example, if a patient's blood pressure does truly drop just from the belief that they may have received denervation, this has been termed the placebo effect. In addition, adherence to prescribed antihypertensive regimens is frequently reported to be imperfect. 9, 10 If undergoing a new intervention causes patients to increase adherence to already prescribed antihypertensive therapy, blood pressure will fall regardless of the biological effect of the new intervention. The general statistical name for these phenomena is confounding. For clarity, this might also be termed the nondenervation effect of the denervation procedure, which includes the placebo effect.
Protection Against These 3 Biases
For a study to quantify the effect truly attributable to the intervention itself, it must build in protection from these 3 biases. Adding a control group protects against the first type of bias, regression to the mean, by ensuring that it is present equally in both arms of the trial. Adding either blinding of the physician or removing the physician from the data collection process by using blood pressure monitoring protects against the second type of bias, asymmetrical data handling. Adding blinding of the patient through a sham procedure protects against the third type of bias, the nondenervation effect, by ensuring that any placebo effect and change in drug compliance not because of the therapy will manifest equally in both arms.
Although previous meta-analyses have aimed to identify the sources of bias in denervation trials, [5] [6] [7] 11 in this new analysis, for the first time, we use the availability of numerous studies with different designs to focus on systematically quantifying the contributions of these 3 biases to the unintentionally overoptimistic single-arm studies using office blood pressures.
Methods

Data Sources and Search Strategy
Renal denervation studies, including ≥5 patients and measuring office or ambulatory blood pressures, quoting baseline and final values, were identified using the search term renal and denervation on the MEDLINE and EMBASE databases without language restrictions (January 2009 to December 2014). Controlled trials were not eligible for inclusion if the control arm received a separate active intervention. Studies were analyzed by 2 reviewers (J.P.H. and A.H.) independently, with a third author (D.P.F.) available to resolve conflicts.
Data Abstraction
From each study report, the following parameters were extracted: the number of patients (for both office and ambulatory pressure monitoring), baseline and final office blood pressures, SD of office blood pressure change, baseline and final ambulatory blood pressures, SD of ambulatory blood pressure change, mean or median time to followup, catheter used, mean age, proportion of patients who were men, proportion of patients who were diabetic, ethnicity, and the mean number of antihypertensive drugs taken at baseline.
Studies were then categorized by whether they used (1) unblinded office pressure changes in a single group of patients, that is, no control group; (2) unblinded office pressure changes in randomized trials, that is, the control-subtracted change in office pressure in an unblinded trial; (3) unblinded ambulatory pressure changes; or (4) blinded data from a randomized trial. Each trial could contribute data to >1 category. Readers should be aware that we cannot be certain whether individual patients might have appeared in >1 publication.
WHAT IS KNOWN
• Over a hundred trials of renal denervation, including randomized controlled trials, show startlingly large effect sizes. • The largest randomized trial, and the first to be blinded, was equally startling in showing no significant effect.
WHAT THE STUDY ADDS
• Adding a control group without blinding is far less helpful in resisting bias than commonly assumed. • Most of the bias in renal denervation trials arise from patients' and physicians' knowledge of treatment allocation. • Future device trials should not report effect sizes except by comparison with blinded placebo (sham) procedure, to avoid waste of research resources. January 2016
Statistical Methods
Data were quantitatively synthesized by an inverse-variance weighted meta-analysis using a random-effects model. For trials that did not publish the SD of pressure changes, we imputed the SD from those that did. Statistical analyses were performed using Microsoft Excel 2010, R, 12 the graphics package ggplot2, 13 and the meta-analysis package metafor (version 1.9). 14
Quantification of the Components of Bias
There are 3 broad classes of reason that cause trials to overestimate blood pressure effects of therapy: (1) unrepresentatively high estimate of pretherapy blood pressure (regression to the mean), (2) unrepresentatively low estimate of post-therapy blood pressure (asymmetrical data handling), and (3) a true change in blood pressure but not caused by the intervention (confounding or nondenervation effect).
The magnitude of these can be calculated as described below.
Effect Size of Regression to the Mean
We calculated the magnitude of regression to the mean as the drop in office blood pressure in patients treated in the control group of unblinded trials. That the potential for such a drop in the control arm is the reason to have a control arm and to subtract the control arm drop from the active arm drop when estimated the therapy effect size.
Effect Size of Asymmetrical Data Handling
We calculated the magnitude of the effect of asymmetrical data handling as the difference between physician-documented (office) and machine-documented (ambulatory) blood pressure drops, in unblinded trials that reported both. We have previously used this technique to demonstrate the effect of this bias in antihypertensive drug trials. 5
Effect Size of Confounding, the Nondenervation Effect
We calculated the magnitude of the effect of the nondenervation effect as the difference between ambulatory systolic blood pressure drops in patients receiving denervation in unblinded trials and ambulatory systolic blood pressure drops in blinded trials. This is because the use of ambulatory blood pressures in unblinded trials avoids the first 2 sources of bias, although blinded trials avoid all 3.
Results
Identification of Eligible Studies
Our search strategy identified 2150 reports. Of these, 1665 reports were excluded on the basis of their abstract, leaving 485 reports. Of these, 337 were excluded from further analysis ( Figure 1 ). The full citation details are in given Appendix I in the Data Supplement. A total of 148 studies were eligible for meta-analysis. These included 140 nonrandomized trials, 6 unblinded randomized trials, and 2 blinded trials; 128 trials measured office blood pressure changes, and 79 trials measured ambulatory blood pressure changes. The baseline characteristics are shown in Table 1 .
Influence of Trial Design on the Reported Effect Size of Renal Denervation
We categorized the results from the 148 trials into 4 classes.
Unblinded office single arm: the office blood pressure changes in the patients undergoing renal denervation in nonrandomized trials.
Unblinded office randomized: the control-subtracted office blood pressure changes in unblinded randomized controlled trials.
Unblinded ambulatory: the ambulatory blood pressure changes in patients undergoing renal denervation in unblinded trials.
Blinded: the control-subtracted blood pressure changes in blinded sham-controlled trials. The measurement strategy (office or ambulatory) specified as the primary end point was used for each trial.
Some studies could provide data for multiple groups. The full results for individual trials are given in Appendix II in the Data Supplement. The results for the meta-analyses of the pressure changes across the 4 trial designs are shown in Table 2 . In the unblinded office single-arm studies, the effect size was −23.6 mm Hg. In the unblinded office randomized studies, the effect size was −29.1 mm Hg. In the unblinded ambulatory studies, the effect size was −11.2 mm Hg. In the blinded studies, the effect size was −2.9 mm Hg. These results of individual trials and the meta-analyzed estimates of effect size are shown in Figure 2 . The Forest plots for the meta-analysis of each of the 4 trial designs are available in Appendix III in the Data Supplement. Trial design was significantly associated with the reported effect size (P<0.001).
Estimates of Bias
Regression to the Mean
In the active arm of 6 open-label randomized trials of 326 patients, the blood pressure change was −30.2 mm Hg (−26.7 to −33.6). The same trials included 200 patients in control arms, who did not receive denervation. Control-subtracted office blood pressure changes were similar, −29.1 mm Hg (−25.2 to −33.1). Our estimate of regression to the mean is the difference between these 2, −1.0 mm Hg (95% confidence interval, −6.3 to 4.2; P=0.71; Figure 3 , left).
Asymmetrical Data Handling
There were 58 open-label trials of 1751 patients measuring both office and ambulatory blood pressures during followup. The change in office blood pressure was −22.1 mm Hg (−19.7 to −24.5). The change in ambulatory blood pressure was lower, −10.5 mm Hg (−9.7 to 11.2; P<0.0001).
The difference between these 2 values is our estimate of the magnitude of asymmetrical data handling, which was −10.8 mm Hg (95% confidence interval, −8.8 to −12.9; P<0.0001; Figure 3 , middle).
Nondenervation Effect
In the 76 open-label trials of 2293 patients measuring ambulatory blood pressure, the change in ambulatory blood pressure was −11.2 mm Hg (−10.0 to −12.4; Table 2 ). In the 2 blinded trials of 591 patients, the change in blood pressure was −2.9 mm Hg (−6.3 to 0.4; Table 2 ).
The difference between these 2 values is our estimate of the magnitude of the nondenervation effect, which was −8.3 mm Hg (−4.7 to −11.8; P<0.0001; Figure 3 , right).
Discussion
The estimates of the blood pressure reductions of renal denervation studies for hypertension vary from a reduction of 59 15 to 0 16 mm Hg. This spans 148 studies of 6114 patients with a cumulative follow-up of 4045 patient-years. Because the studies have used a wide variety of designs, it is possible to analyze the links between study design and the results reported.
Office Blood Pressure Reductions Are Much Larger Than Ambulatory Blood Pressure Reductions But Only in Unblinded Trials
The early reports of renal denervation emphasize the much larger reductions in office than ambulatory blood pressure. Both sets of pressures are measured by using a machine, but only in the former is there easy opportunity for remeasuring if the results do not fit clinical expectations. This contrast is not observed in the blinded data.
Antihypertensive medications show the same pattern. 5 Single-armed studies and unblinded RCTs show larger office blood pressure reductions than ambulatory. The blinded RCTs show the drugs to have an identical effect on office and ambulatory pressures.
The mean 24-hour blood pressure from ambulatory monitoring recordings is naturally lower than that of office blood pressures. This is because a patient's blood pressure tends to be higher during an office visit than other times during the day and tends to be lower during the night. Because of this, meta-analyses support lower thresholds for treatment for readings from ambulatory blood pressures. 17 Nevertheless, the incremental effect beyond a blinded control arm, regardless of whether the intervention is pharmacological 5 or renal denervation, seems to be consistent between office and ambulatory blood pressure monitoring. This suggests that there is an equal effect on blood pressure, evident in blinded RCTs, which can be obscured when blinding is omitted.
Unblinded Trial Design Is Associated With Greater Office Blood Pressure Reductions in the Active Arm But Smaller Reductions in the Control Arm
The unblinded randomized controlled trials showed no difference in office systolic blood pressure in the control arm. 3 The corresponding drop in the control arm of the blinded Symplicity HTN-3 trial was −11.7 mm Hg (P<0.001). 4 The active arms also showed different results but with the reverse pattern. The unblinded trials showed a larger ≈30mm Hg reduction in office blood pressure than the blinded Symplicity HTN-3, 14.1 mm Hg.
A variety of reasons have been proposed both by the authors 18 and other experts 19, 20 for the Symplicity HTN-3 results, which were considered surprising at the time. One proposal was that renal denervation had not been performed correctly, perhaps because some centers lacked experience. However, it is notable that there are numerous reports of first experiences of renal denervation in individual centers showing strong positive results (Appendix I in the Data Supplement). Another proposed theory was that the number of lesions performed in Symplicity HTN-3 was inadequate. However, many studies that showed effect sizes 10× larger did not describe any more training or practice than Symplicity HTN-3. Another suggestion, from a post hoc analysis of the trial, was that the use of aldosterone antagonists and the number of ablations may be associated with a greater reduction in blood pressure. 18 However, the most striking difference between Symplicity HTN-3 and the strongly positive studies that preceded it was that both physicians and patients were blinded. In summary, among patients who have not had denervation, knowledge that a renal denervation may have been performed leads to greater blood pressure reductions being documented. Furthermore, among patients who have had denervation, certainty that a denervation has been performed leads to greater blood pressure reductions being documented.
Adding a Randomized Control Arm Does Not Reduce Bias Unless It Is Blinded
RCTs are recognized as the most bias-resistant method for assessing the effect of an intervention. However, undue emphasis solely on the presence of a control arm and randomization may lead us to assume incorrectly that other elements do not make a large contribution to unintentional bias in results. Our analysis indicates that moving forward from a single-armed study to an unblinded randomized controlled trial does not usefully reduce bias. This is because 2 sources of bias remain.
First, clinical research staff are aware of treatment allocation. They report larger drops in office pressure in the active arm than the control arm. However, this is not the totality of the bias because it cannot explain the larger drops in ambulatory pressure in the active arm than in the control arm.
Second, patients are aware of treatment allocation. This is the most likely cause of the (control subtracted) ambulatory blood pressure effect size being much larger in the unblinded than the blinded trials.
These data indicate that despite the extra effort involved, instituting blinding may be essential if the effect size of the intervention is to be quantified reliably. This principle likely holds for all device therapies for hypertension.
Clinical Implications
For novel therapies of hypertension, it is unwise to rely on unblinded studies, regardless of whether they are randomized. This may be valuable to know because blinded studies of an interventional procedure require a placebo procedure, sometimes called a sham procedure. Because a placebo procedure entails a risk to the research participant, some authors have argued that the presence of a sham procedure is unethical. 21 However, the results of our study show that without a placebo procedure, the overall results of the study demonstrate a large positive bias, reporting an unintentionally misleading result. This means that the risk undergone by the active arm participants has not been for the sake of reliable information, which could be argued to be a waste. In the longer term, if clinicians and regulators do not suspect the magnitude of potential bias, many more subsequent clinical patients may undergo an intervention based on an incorrect belief of its effect size.
It is unlikely that the phenomena explored here are unique to procedural interventions. It is quite possible that they may be present to a similar extend in pharmacological strategies. The unique opportunity in renal denervation is the large number of studies investigating a single intervention for 1 disease with a small number of different designs that can be readily categorized. We have previously noted similar associations between study design and effect size in trials of antihypertensive drugs. 5 Figure 2 . Relationship between trial design and the reductions in office and ambulatory blood pressures. Each data point represents a trial. The area of the data point is proportional to the trial size. Red diamonds indicate the meta-analyzed estimate of the effect size for each trial design ( Table 2 ). January 2016
Study Limitations
In our article, for simplicity, we describe the change in blood pressure in the control arm as synonymous with regression to the mean. In fact, there are multiple reasons why the process of enrollment of patients with pressures above a threshold might lead to lower pressures subsequently. The statistical term regression to the mean principally refers to the enrollment pressures tending to be higher than the patients' individual long-term averages through spontaneous biological variability. However, an additional reason why enrollment pressures may be artificially high is that patients who have by chance skipped tablets will be more likely to have pressures high enough for enrollment. Subsequent measurements will, therefore, tend to be lower. Moreover, the increased contact with healthcare professionals in a trial, even in an unblinded control arm, might encourage higher adherence (an example of the Hawthorne effect). Surprisingly, the whole of this bias, on average across trials, amounts to only 1 mm Hg (95% confidence interval, −6.27 to 4.24). It is also possible that our estimate of regression to the mean (defined as the blood pressure drop in the control arm) has been blunted by the same process underlying asymmetrical data handling, namely remeasuring. For example, if a patient in a control arm demonstrated a large unexpected blood pressure drop, this measurement might have been repeated.
It is possible that denervation has different effect sizes in different groups of patients. The problem with using unblinded data to probe this is that most of the observed blood pressure changes are not actually from the biological effect from denervation but the aforementioned biases. Using these data to identify high-responding subgroups may, therefore, inadvertently identify the cases of greater unintentional bias.
The populations studied by the blinded randomized trials may well have been different in various characteristics from those in the other trials. For example, the prevalence of diabetes mellitus was 50% in the blinded trials but 31.2% and 36.5% in the unblinded randomized and non-randomized trials, respectively (Table 1 ). Speculation can also be raised on whether these differences are the explanation for the differences in reported effect size. However, in some cases, data are available to test the plausibility of such a hypothesis. In the cases of diabetes mellitus, for example, the trials themselves have shown no difference in effect size between diabetics and nondiabetics. 4, 18 We can be confident that such a comparison is adequately powered to test whether diabetes mellitus could explain the disparity between trial designs. This is because, for 30-mm Hg difference in reported effect size to be caused by a 20-absolute percentage point difference in prevalence of diabetes mellitus, the effect of diabetes mellitus must be to attenuate the effect size of renal denervation by 30×100÷20, which is 150 mm Hg. All the within-study comparisons of diabetics versus nondiabetics would have been able to detect a difference in effect size of 150 mm Hg. It is also possible that multiple such confounders might be simultaneously involved, all, by coincidence, in the same direction. The fact that there is no evidence for such a coincidence 4, 18 does not make it impossible. The only reason to prefer the explanation that it is because of randomization and blinding is that there is evidence for this.
We do not know why there are much larger effects in office blood pressure than in ambulatory blood pressure. In public at an academic conference, most physicians are happy to state that in routine clinical practice, they would remeasure values that are unexpectedly high. 8 Whether they do this in research practice is unknown but would be an explanation for our findings. Some of the major unblinded trials, such as Symplicity HTN-2, 3 specified in detail that blood pressure measurements were not to be discarded. It is not known whether these specifications were fully implemented on every occasion. All we know is that oscillometric measurements printed and transferred to the research records by human (office measurements) showed a 24-mm Hg difference between groups, whereas oscillometric measures automatically accumulated and documented by machine (ambulatory measurements) showed a-11 mm Hg difference.
Our analysis aims at inclusivity. Readers should bear in mind that some centers may have contributed multiple studies to the literature. [22] [23] [24] [25] [26] [27] [28] [29] It is conceivable that data from some individual patients may appear in separate publications. Although it is not possible to exactly quantify this, we advise readers that the true errors bars on our estimates may need to be slightly wider than those we calculate, which are based on the assumption that that published datasets are of different patients. Furthermore, some have raised concerns on some of the literature. 30 Our study includes all of the eligible trials on the basis that any methodological shortcomings may be at least partially responsible for the discrepancies in results to date.
Finally, there are trials that did not fit in to the categories we specified to quantify these distinct biases. The DENERHTN trial, 31 for example, was a pragmatic randomized controlled trial where a firm stepped-care protocol of antihypertensive treatment was applied in both denervation and control patients. Unfortunately, its data are not eligible for our analysis because its protocol included aggressive uptitration of antihypertensive drugs. If the DENER-HTN data were added to a group, the effect size in that group would be inflated by the effect of the intensification of medical therapy, and our estimates of effect size would be inappropriately altered.
Conclusions
The large number of studies, covering a spread of designs, permits assessment of the 3 biases common to trials of novel antihypertensive therapies. Of the 3, regression to the mean seems to be the smallest. Unfortunately, this is the only bias that is eliminated merely by the inclusion of a randomized control arm to an unblinded study. The remaining 2 biases are caused by knowledge of treatment allocation, by the staff responsible for blood pressure measurement (≈11 mm Hg) and by the patient (≈8 mm Hg), respectively. Using ambulatory blood pressures, which the physician cannot easily repeat if seemingly unrepresentative, may mitigate the former but not the latter.
Eliminating these 2 biases that total ≈19 mm Hg in the trials so far requires blinding. This means a placebo (sham) procedure is essential to prevent substantial overestimation of effect size.
